Following the acquisition, Monistat will continue to be available through existing retail channels and will be marketed under Insight Pharmaceuticals growing portfolio of products.
Insight Pharma CEO Gary Downing said this acquisition, along with e.p.t, has increased their revenues by nearly four times in the last 12 months.
"Additionally, as part of the e.p.t transaction, Insight acquired the Uristat urinary pain treatment brand and is preparing to re-launch the brand," Downing said.